This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech

The Top-Performing Biotech Stock During a Sizzling First Quarter

The Top-Performing Biotech Stock During a Sizzling First Quarter

That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

04/01/15 - 09:30 AM EDT

Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame

Current Sarepta Chief Medical Officer Ed Kaye is taking over the CEO role on an interim basis until a permanent chief can be found to replace Chris Garabedian.

03/31/15 - 09:57 PM EDT

Array BioPharma CEO Sees Big Opportunities in the Future Array BioPharma CEO Sees Big Opportunities in the Future

Array BioPharma CEO Sees Big Opportunities in the Future

Ron Squarer, CEO of Array BioPharma, says the company has several late-stage clinical trials underway, and their success could build momentum.

03/31/15 - 04:27 PM EDT

Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame

Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame

Current Sarepta Chief Medical Officer Ed Kaye is taking over the CEO role on an interim basis until a permanent chief can be found to replace Chris Garabedian.

03/31/15 - 09:57 PM EDT

Immunogen (IMGN) Stock Gains Today After Selling Kadcyla Royalty Rights for $200 Million

Immunogen (IMGN) Stock Gains Today After Selling Kadcyla Royalty Rights for $200 Million

  • Tickers in this article:
  • IMGN

Immunogen (IMGN) shares rose today after securing $200 million in financing by selling the royalty rights for its breast cancer treatment Kadcyla.

03/31/15 - 12:40 PM EDT

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble

  • Tickers in this article:
  • NBI
  • XBI

Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?

03/31/15 - 11:30 AM EDT

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.

03/31/15 - 09:39 AM EDT

How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition

How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition

Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.

03/31/15 - 09:13 AM EDT

Genfit's French Fans Fume Following Failure of Fatty Liver Drug

Genfit's French Fans Fume Following Failure of Fatty Liver Drug

French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.

03/31/15 - 08:51 AM EDT

Stocks Recover From Last Week's Selloff, but Expect More Volatility Ahead

Stocks Recover From Last Week's Selloff, but Expect More Volatility Ahead

After a major sell-off in the biotech space last week, the Dow Jones Industrial Average rose 1.5% on Monday amid a flurry of M&A activity in the pharmaceuticals space.

03/30/15 - 11:22 AM EDT

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

The Israeli drug company thinks the biopharmaceutical drug developer will strengthen its position in its core central nervous system segment.

03/30/15 - 01:25 PM EDT

UnitedHealth Group (UNH) Stock Gains Today on $12.8 Billion Acquisition of Catamaran

UnitedHealth Group (UNH) Stock Gains Today on $12.8 Billion Acquisition of Catamaran

  • Tickers in this article:
  • UNH

UnitedHealth Group (UNH) shares are rising on heavy volume after the company announced the purchase of Catamaran (CTRX) for nearly $13 billion.

03/30/15 - 11:23 AM EDT

Intrexon (XON) Stock Spikes Today on Developmental Collaboration with Merck Serono

Intrexon (XON) Stock Spikes Today on Developmental Collaboration with Merck Serono

  • Tickers in this article:
  • XON

Intrexon (XON) shares are gaining on heavy volume today following CAR-T treatment collaboration with Merck Serono.

03/30/15 - 10:29 AM EDT

Teva Buying Auspex Pharma for $3.5 Billion in Bid to Restart Growth

Teva Buying Auspex Pharma for $3.5 Billion in Bid to Restart Growth

Teva said it would acquire smaller companies as a way to offset the expected revenue hit coming when its multiple sclerosis drug Copaxone faces generic competition in September.

03/30/15 - 07:41 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,614.54 -161.58 -0.91%
S&P 500 2,049.82 -18.07 -0.87%
NASDAQ 4,850.0680 -50.8170 -1.04%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs